QUÉBEC CITY, QC, Jan. 8, 2014
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that it has commenced an
underwritten public offering of units (the "Offering"),
consisting of common shares and warrants to purchase common shares.
The pricing and number of Units as well as the exercise price and
duration of the warrants will be determined in the course of
marketing.
Canaccord Genuity is acting as sole book-running manager for the
proposed Offering. The proposed Offering is subject to customary
conditions, including the approval of the Toronto Stock Exchange
("TSX") and The NASDAQ Stock Market ("NASDAQ"), and there can be no
assurance as to whether or when the proposed Offering may be
completed, or as to the actual size or terms of the Offering. The
Company has no intention of listing the warrants on the TSX or
NASDAQ.
The Offering is being conducted pursuant to the Company's
effective shelf registration statement on Form F-10 filed with the
U.S. Securities and Exchange Commission (the "SEC"), its
corresponding Canadian base shelf prospectus and an exemption from
the Autorité des marches financiers permitting the Company
to offer common shares and warrants in the United States. The proposed offering will
be made only by means of a preliminary prospectus supplement, a
final prospectus supplement and the accompanying short form base
shelf prospectus. When available, copies of the preliminary
prospectus supplement, the final prospectus supplement and the
accompanying short form base shelf prospectus may be obtained upon
request by contacting Canaccord Genuity Inc., Attention: Syndicate
Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone
at (617) 371-3900. Electronic copies of the preliminary
prospectus supplement, the final prospectus supplement and the
accompanying short form base shelf prospectus will also be
available free of charge at www.sedar.com and www.sec.gov,
respectively.
This press release does not constitute an offer to sell or
a solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing novel treatments in oncology and
endocrinology. The Company's pipeline encompasses compounds from
drug discovery to regulatory approval. For more information, visit
www.aezsinc.com.
This press release contains forward-looking statements made
pursuant to the safe harbour provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties that could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the risk that safety and efficacy data from any of our
Phase 3 trials may not coincide with the data analyses from
previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to efficiently commercialize one or more of
its products or product candidates, the ability of the Company to
take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult
the Company's quarterly and annual filings with the Canadian and
U.S. securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The
Company does not undertake to update these forward-looking
statements. We disclaim any obligation to update any such factors
or to publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future
results, events or developments, unless required to do so by a
governmental authority or by applicable law.
SOURCE Aeterna Zentaris Inc.